Literature DB >> 9127624

Long-term management of gastroesophageal reflux disease and its complications.

J E Richter1.   

Abstract

Although gastroesophageal reflux disease (GERD) is believed to be primarily a motor disorder, current medical therapy is based on the inhibition of acid secretion, since it is the deleterious effects of the acidic refluxate that lead to the symptoms and complications of GERD. Goals of long-term management include the relief of symptoms, healing of esophagitis and prevention of its relapse, and prevention of complications with safe, cost-effective therapy. Maintenance therapy depends on disease severity. Prokinetic drugs have a limited role except in symptomatic nonerosive GERD. Likewise, H2-receptor antagonists are useful in relapsing, nonerosive GERD or in cases of mild initial esophagitis. For severe reflux esophagitis, even high doses of H2-receptor antagonists do not appear to be as effective as proton pump inhibitors. GERD patients with severe reflux esophagitis or complications such as peptic stricture or Barrett's esophagus should be maintained on proton pump inhibitors such as lansoprazole or omeprazole. For young and otherwise healthy patients, antireflux surgery is a viable option.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9127624

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  13 in total

1.  What is heartburn worth? A cost-utility analysis of management strategies.

Authors:  G R Heudebert; R M Centor; J C Klapow; R Marks; L Johnson; C M Wilcox
Journal:  J Gen Intern Med       Date:  2000-03       Impact factor: 5.128

2.  Management of benign oesophageal strictures.

Authors:  Nicholas E Burr; Simon M Everett
Journal:  Frontline Gastroenterol       Date:  2019-01-07

3.  Temperature-monitored optical treatment for radial tissue expansion.

Authors:  Jinoh Bak; Hyun Wook Kang
Journal:  Lasers Med Sci       Date:  2017-03-29       Impact factor: 3.161

Review 4.  Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.

Authors:  Katsuhiko Iwakiri; Yoshikazu Kinoshita; Yasuki Habu; Tadayuki Oshima; Noriaki Manabe; Yasuhiro Fujiwara; Akihito Nagahara; Osamu Kawamura; Ryuichi Iwakiri; Soji Ozawa; Kiyoshi Ashida; Shuichi Ohara; Hideyuki Kashiwagi; Kyoichi Adachi; Kazuhide Higuchi; Hiroto Miwa; Kazuma Fujimoto; Motoyasu Kusano; Yoshio Hoshihara; Tatsuyuki Kawano; Ken Haruma; Michio Hongo; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-06-21       Impact factor: 7.527

5.  Esomeprazole: a review of its use in the management of acid-related disorders in the US.

Authors:  Lesley J Scott; Christopher J Dunn; Gordon Mallarkey; Miriam Sharpe
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Lansoprazole: an update of its place in the management of acid-related disorders.

Authors:  A J Matheson; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial.

Authors:  M P Schwartz; H Wellink; H G Gooszen; J M Conchillo; M Samsom; A J P M Smout
Journal:  Gut       Date:  2006-06-08       Impact factor: 23.059

Review 8.  Lansoprazole for maintenance of remission of erosive oesophagitis.

Authors:  James W Freston; Robert L Jackson; Bidan Huang; E David Ballard
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Esomeprazole: a review of its use in the management of acid-related disorders.

Authors:  Lesley J Scott; Christopher J Dunn; Gordon Mallarkey; Miriam Sharpe
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Empiric dilation in non-obstructive dysphagia.

Authors:  Jeffrey S Olson; David A Lieberman; Amnon Sonnenberg
Journal:  Dig Dis Sci       Date:  2007-10-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.